The short version of FSFI desire score fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-13. Anything still debated is marked as such rather than presented as settled.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
delocalized electron Any electron in a molecule, ion, or solid metal that is not associated with an individual atom or covalent bond. The term may refer to electrons involved in resonance in conjugated systems or aromatic compounds; to free electrons which facilitate electrical conductivity; or to electrons within delocalized molecular orbitals encompassing several adjacent atoms.
For voluntary and charitable services to the community in Limavady, County Londonderry. David Gregory Snook. Reading Volunteer, Hampton Primary School, Herne Bay, Kent. For services to Education. Versha Sood-Mahindra. Lately Dementia Lead, BUPA. For services to Community Cohesion and to People with Dementia in Cardiff. Zoe Donna Sookun. Project Manager, Network Rail. For services to the Railway and to Rail Aid for Ukraine. Denise Speight. Chargehand Cleaner, Newcastle City Council. For services to Local Government. Charlotte Jessica Stacey. On Call Firefighter, Oxfordshire Fire and Rescue Service. For services to the community in Oxfordshire. Margaret Pearl Sterling. Teaching Associate, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast. For services to Higher Education in Northern Ireland. Eileen Linda Stewart. Manager, Armagh Business Centre. For services to Entrepreneurship, to Economic Regeneration and to the community in Armagh, Northern Ireland. Gloria Ann Stewart. For services to the community in Sheffield, South Yorkshire. Sheena Stewart. Lately Warden, Chalmers Court Sheltered Housing Complex, Inverarary. For services to the community in Mid-Argyll. Allan Stokoe. For services to the community in Eldon, North Yorkshire. Dr Jill Mary Stoner. Chair, Cromarty Care Project. For services to the community in Cromarty, Ross and Cromarty. Jan Tallis. Founding Chair, Community Schools Trust. For services to Children and Families in the London Borough of Newham. Robert Sherwin Taylor. For services to the community in Shipbourne, Kent.
=== Cultures === Samples undergoing examination for pathogens, primarily in medical microbiology, may be incubated with culture media. Those allow, for example, the description of one or several infectious agents responsible of the clinical signs.
The fluorenylmethoxycarbonyl protecting group (Fmoc) is a base-labile amine protecting group used in organic synthesis, particularly in peptide synthesis. It is popular for its stability toward acids and hydrolysis and its selective removal by weak bases, such as piperidine, without affecting most other protecting groups or sensitive functional groups. Fmoc protection is especially advantageous in solid-phase peptide synthesis (SPPS), where its compatibility with other reagents and ease of removal streamline synthesis workflows. Upon deprotection, Fmoc yields a byproduct (Dibenzofulvene) that can be monitored by UV spectroscopy, allowing for efficient reaction tracking.
SSRIs are effective for the treatment of premature ejaculation. Taking SSRIs on a chronic, daily basis is more effective than taking them prior to sexual activity. The increased efficacy of treatment when taking SSRIs on a daily basis is consistent with clinical observations that the therapeutic effects of SSRIs generally take several weeks to emerge. Sexual dysfunction ranging from decreased libido to anorgasmia is usually considered to be a significantly distressing side effect which may lead to noncompliance in patients receiving SSRIs. However, for those with premature ejaculation, this same side effect becomes the desired effect.
Sources: en.wikipedia.org
Of the subjects who were administered Tepezza, 71% in study 1 and 83% in study 2 demonstrated a greater than 2 mm reduction in proptosis (eye protrusion) as compared to 20% and 10% of subjects who received placebo, respectively. The trials were conducted at 28 sites in Europe and United States. Teprotumumab-trbw was approved for use in the United States in January 2020, for the treatment of adults with thyroid eye disease. The FDA granted the application for teprotumumab-trbw fast-track, breakthrough therapy, priority review, and orphan drug designations. The FDA granted the approval of Tepezza to Horizon Therapeutics Ireland DAC.
=== In tRNA === Wobble pairing rules. Watson–Crick base pairs are shown in bold. Parentheses denote bindings that work but will be favoured less. A leading x denotes derivatives (in general) of the base that follows.
which means that the divergence of the velocity field is zero everywhere. Physically, this is equivalent to saying that the local volume dilation rate is zero, hence a flow of water through a converging pipe will adjust solely by increasing its velocity as water is largely incompressible.
=== Mid-cycle === The absence of GnSAF lowers the threshold for GnRH pulse frequency and amplitude required to stimulate the anterior pituitary to secrete LH. Concurrently, GnRH pulse frequency and amplitude increases, which allows LH secretion significantly higher than basal levels. The LH secretion most noticeable as a LH surge lasting 48 to 72 hours in the middle of the ovarian cycle. Meiosis in the dominant follicle resumes and follicle ruptures shortly after the LH surge. Ovulation can only occur if GnSAF is absent and the mid-cycle LH surge occurs.
Sources: en.wikipedia.org
== Safety and regulation == Active packaging is designed to interact with the packaged product or the surrounding environment. The active function does not remove the requirement for the underlying packaging to comply with applicable food-contact, pharmaceutical, transport, environmental, and product-safety rules. In the European Union, Commission Regulation (EC) No 450/2009 establishes specific requirements for active and intelligent materials intended to come into contact with food. It defines active materials as materials designed to deliberately release or absorb substances in order to extend shelf life or maintain or improve food condition. Substances intended to migrate into food may also be subject to food-additive and labelling requirements. Components positioned behind a functional barrier must remain within applicable migration limits. Intelligent packaging must not provide misleading information about the condition or safety of a product. An indicator that makes spoiled food appear acceptable could create a safety risk. Safety assessment may include:
=== Korean Culture and coffee consumption === The most popular coffee among Koreans is Iced Americano, regardless of weather. Even in the cold winter, Koreans like to drink Iced Americano. AFP has mentioned, in winter the consumption of Iced Americano is greater than warm drinks. For this particular coffee consumption, there's a new phrase created called 'Eoljukah' which means 'iced coffee even if I freeze to death'. The reason that particular drink is popular is because of Korea's fast paced culture. Iced Americano comes out in a short amount of time compared to the other drinks so in fast-paced culture in Korea, most people prefer that drink. In 2019, Hyundai Research Lab found out that the individuals' average yearly consumption of coffee is 353 cups, which is the rate that is twice higher than worldwide average.
As a passenger during a long car drive, when insulin needs are different due to inactivity. While driving on an extended trip, to reduce the risk of hypoglycemia, a lower temporary basal rate may be programmed. During and after spontaneous exercise or sports activities, when the body needs less insulin. During illness or stress, when basal demand increases due to insulin resistance. When blood ketones are present, when additional insulin is needed. When on an extended fast (such as Ramadan, Lent, or Yom Kippur) when basal requirements may be lower. During menses, when additional basal insulin might be needed.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.